Q3/FY2023 FINANCIAL RESULTS
ENDED DECEMBER 31, 2023

from the beginning

Q3/FY2023 FINANCIAL RESULTS ENDED DECEMBER 31, 2023

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

I. Q3/FY2023 Consolidated Financial Results FY2023 Revised Forecasts

• Q3/FY2023 FINANCIAL RESULTS: OVERVIEW

• Q3/FY2023 FINANCIAL RESULTS

• XTANDI & XOSPATA: BUSINESS UPDATE

• PADCEV: BUSINESS UPDATE

• VEOZAH: BUSINESS UPDATE

• IZERVAY: BUSINESS UPDATE

• Q3/FY2023 FINANCIAL RESULTS: COST ITEMS

• FY2023 REVISED FORECAST

II. Initiatives for Sustainable Growth

• INITIATIVES FOR SUSTAINABLE GROWTH: OVERVIEW

• XTANDI AND STRATEGIC PRODUCTS: KEY EVENTS EXPECTED IN FY2023

• PROGRESS IN LATE-STAGE PIPELINE

• ZOLBETUXIMAB: LATEST STATUS

• PROGRESS IN FOCUS AREA APPROACH:CURRENT STATUS OF PROJECTS IN CLINICAL TRIAL

• OPEN INNOVATION INITIATIVES

• PROGRESS IN FY2023 AND FUTURE OUTLOOK

APPENDIX

• Q3/FY2023: REVENUE BY REGION

• Q3/FY2023 ACTUAL: FX RATE

• FY2023 FORECAST: FX RATE & FX SENSITIVITY

• BALANCESHEET & CASHFLOWHIGHLIGHTS

• MAIN INTANGIBLE ASSETS (AS OF DEC 31, 2023)

• CAPITAL ALLOCATION

• ROBUST PIPELINE OF ASTELLAS

• PROGRESS IN OVERALL PIPELINE

• XTANDI AND STRATEGIC PRODUCTS: STATUS UPDATE

• ENZALUTAMIDE(1/2): ANDROGEN RECEPTOR INHIBITOR

• ENZALUTAMIDE(2/2): PHASE 3 STUDY DATA BY DISEASE STAGE

• ENFORTUMAB VEDOTIN(EV)(1/4): NECTIN-4 TARGETED ADCOVERALL UC PROGRAM

• ENFORTUMAB VEDOTIN(EV)(2/4): CLINICAL STUDIES

• ENFORTUMAB VEDOTIN(EV)(3/4): STUDY DATA BY DISEASE STAGE OF UC

• ENFORTUMAB VEDOTIN(EV)(4/4): FUTURE OUTLOOK

GILTERITINIB: FLT3 INHIBITOR

• ZOLBETUXIMAB: ANTI-CLAUDIN 18.2 MONOCLONAL ANTIBODY

• FEZOLINETANT: NK3 RECEPTOR ANTAGONIST

• AVACINCAPTAD PEGOL(ACP): COMPLEMENT C5 INHIBITOR / PEGYLATED RNA APTAMER

• FOCUS AREA APPROACH: KEY EVENTS EXPECTED IN FY2023

• ON THE FOREFRONT OF HEALTHCARE CHANGE

Questions

• Questions 1

• Questions 2

• Questions 3

• Questions 4

• Questions 5

• Questions 6

• Questions 7

• Questions 8

• Questions 9